Nifty
:
23123.65
Sensex
:
74616.58
155.40 (0.68%)
509.73 (0.69%)
Nifty
Sensex
:
:
23123.65
74616.58
155.40 (0.68%)
509.73 (0.69%)

Granules India Ltd.

Pharmaceuticals & Drugs - API

Rating :
72/99

BSE: 532482 | NSE: GRANULES

NSE BSE
638.80
07-Apr-2026
  • Open
  • High
  • Low
  • Previous Close
  •  644
  •  644.3
  •  628.75
  •  644.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  776978
  •  493895507.55
  •  649
  •  422

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 15,828.03
  • 29.02
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 16,846.46
  • 0.23%
  • 3.83

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 38.02%
  • 5.70%
  • 19.09%
  • FII
  • DII
  • Others
  • 15.31%
  • 13.25%
  • 8.63%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.69
  • 6.72
  • -0.22

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.10
  • 2.02
  • 0.69

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.91
  • -1.81
  • -0.98

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.31
  • 19.65
  • 25.84

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.04
  • 3.33
  • 3.40

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.43
  • 12.04
  • 13.20

Earnings Forecasts:

(Updated: 04-04-2026)
Description
2024
2025
2026
2027
Adj EPS
20.69
23.41
29.17
35.9
P/E Ratio
30.87
27.29
21.90
17.79
Revenue
4481.61
5276.03
6095.53
6895.54
EBITDA
945.24
1140.13
1372.64
1604.69
Net Income
501.52
577.04
742.14
900.96
ROA
8.52
P/B Ratio
4.17
3.52
3.10
2.45
ROE
14.45
13.88
14.35
14.66
FCFF
195
-286.11
293.15
474.06
FCFF Yield
1.2
-1.76
1.81
2.92
Net Debt
842.63
554.7
398.4
-682.3
BVPS
153.19
181.54
205.86
260.75

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Net Sales
1,387.94
1,137.70
22.00%
1,296.99
966.62
34.18%
1,210.11
1,179.87
2.56%
1,197.43
1,175.78
1.84%
Expenses
1,079.84
907.40
19.00%
1,018.76
763.30
33.47%
963.39
920.60
4.65%
945.07
920.08
2.72%
EBITDA
308.10
230.29
33.79%
278.23
203.32
36.84%
246.72
259.27
-4.84%
252.36
255.70
-1.31%
EBIDTM
22.20%
20.24%
21.45%
21.03%
20.39%
21.97%
21.07%
21.75%
Other Income
-3.64
5.68
-
-1.15
3.25
-
16.34
2.06
693.20%
1.92
1.87
2.67%
Interest
28.69
26.57
7.98%
29.19
25.67
13.71%
23.78
27.02
-11.99%
23.98
28.76
-16.62%
Depreciation
73.53
56.61
29.89%
72.02
52.52
37.13%
68.85
52.87
30.23%
63.50
53.18
19.41%
PBT
202.23
152.79
32.36%
175.87
128.38
36.99%
144.53
181.44
-20.34%
197.55
175.64
12.47%
Tax
52.02
35.19
47.83%
45.26
31.15
45.30%
31.89
46.79
-31.84%
45.52
45.99
-1.02%
PAT
150.21
117.60
27.73%
130.61
97.23
34.33%
112.64
134.65
-16.35%
152.03
129.65
17.26%
PATM
10.82%
10.34%
10.07%
10.06%
9.31%
11.41%
12.70%
11.03%
EPS
6.19
4.85
27.63%
5.38
4.01
34.16%
4.64
5.56
-16.55%
6.27
5.35
17.20%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
5,092.47
4,481.61
4,506.37
4,511.92
3,764.92
3,237.54
2,598.65
2,279.20
1,684.62
1,410.57
1,357.18
Net Sales Growth
14.18%
-0.55%
-0.12%
19.84%
16.29%
24.59%
14.02%
35.29%
19.43%
3.93%
 
Cost Of Goods Sold
1,809.96
1,725.70
2,021.25
2,307.28
1,883.64
1,391.28
1,280.93
1,255.56
896.32
679.63
725.03
Gross Profit
3,282.51
2,755.91
2,485.12
2,204.63
1,881.28
1,846.27
1,317.72
1,023.64
788.30
730.93
632.15
GP Margin
64.46%
61.49%
55.15%
48.86%
49.97%
57.03%
50.71%
44.91%
46.79%
51.82%
46.58%
Total Expenditure
4,007.06
3,536.37
3,650.39
3,598.60
3,043.30
2,382.31
2,073.33
1,895.16
1,406.20
1,111.73
1,081.29
Power & Fuel Cost
-
100.74
100.64
95.69
74.66
68.85
59.74
57.67
48.22
38.67
34.97
% Of Sales
-
2.25%
2.23%
2.12%
1.98%
2.13%
2.30%
2.53%
2.86%
2.74%
2.58%
Employee Cost
-
619.66
550.24
420.35
366.44
324.29
259.04
209.82
165.21
140.19
117.57
% Of Sales
-
13.83%
12.21%
9.32%
9.73%
10.02%
9.97%
9.21%
9.81%
9.94%
8.66%
Manufacturing Exp.
-
469.82
408.01
273.93
298.74
228.39
177.94
157.62
120.84
86.23
65.02
% Of Sales
-
10.48%
9.05%
6.07%
7.93%
7.05%
6.85%
6.92%
7.17%
6.11%
4.79%
General & Admin Exp.
-
279.35
211.99
187.96
134.41
172.28
125.63
99.96
83.05
70.02
62.33
% Of Sales
-
6.23%
4.70%
4.17%
3.57%
5.32%
4.83%
4.39%
4.93%
4.96%
4.59%
Selling & Distn. Exp.
-
297.79
290.63
280.00
247.45
159.80
112.17
91.84
83.08
81.37
67.75
% Of Sales
-
6.64%
6.45%
6.21%
6.57%
4.94%
4.32%
4.03%
4.93%
5.77%
4.99%
Miscellaneous Exp.
-
43.32
67.62
33.38
37.96
37.42
57.88
22.69
9.49
15.61
67.75
% Of Sales
-
0.97%
1.50%
0.74%
1.01%
1.16%
2.23%
1.00%
0.56%
1.11%
0.64%
EBITDA
1,085.41
945.24
855.98
913.32
721.62
855.23
525.32
384.04
278.42
298.84
275.89
EBITDA Margin
21.31%
21.09%
18.99%
20.24%
19.17%
26.42%
20.22%
16.85%
16.53%
21.19%
20.33%
Other Income
13.47
12.92
4.40
14.29
18.22
26.88
36.56
26.68
10.84
9.93
5.62
Interest
105.64
103.24
105.82
55.93
23.21
26.28
27.02
28.46
33.06
32.26
37.07
Depreciation
277.90
225.50
207.33
184.49
158.63
151.46
136.95
105.48
76.20
71.51
58.40
PBT
720.18
629.42
547.23
687.17
558.00
704.36
397.90
276.78
180.00
204.99
186.03
Tax
174.69
158.65
141.92
170.58
145.24
154.91
115.73
89.11
63.40
65.20
61.15
Tax Rate
24.26%
24.03%
25.93%
24.82%
26.03%
21.99%
27.19%
32.20%
35.22%
31.81%
32.87%
PAT
545.49
501.52
405.31
516.60
412.76
549.46
335.40
236.41
132.59
164.52
124.89
PAT before Minority Interest
545.49
501.52
405.31
516.60
412.76
549.46
335.40
236.41
132.59
164.52
124.89
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
10.71%
11.19%
8.99%
11.45%
10.96%
16.97%
12.91%
10.37%
7.87%
11.66%
9.20%
PAT Growth
13.85%
23.74%
-21.54%
25.16%
-24.88%
63.82%
41.87%
78.30%
-19.41%
31.73%
 
EPS
22.01
20.24
16.36
20.85
16.66
22.17
13.54
9.54
5.35
6.64
5.04

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
3,715.58
3,225.54
2,834.91
2,586.54
2,173.27
1,843.72
1,529.47
1,304.18
903.60
661.60
Share Capital
24.25
24.24
24.20
24.80
24.77
25.42
25.42
25.38
22.87
21.67
Total Reserves
3,677.62
3,183.00
2,792.68
2,545.01
2,126.23
1,800.02
1,493.09
1,273.38
878.28
611.13
Non-Current Liabilities
465.99
176.04
254.73
282.83
366.30
485.98
552.63
488.19
187.99
246.62
Secured Loans
311.51
68.97
148.64
233.70
333.81
414.83
478.78
433.13
123.90
183.66
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
6.69
0.00
0.00
0.34
0.55
Long Term Provisions
31.76
37.88
29.26
28.31
24.84
21.50
12.58
7.70
7.25
5.58
Current Liabilities
2,003.16
2,082.29
1,813.50
1,641.60
1,173.10
893.40
896.48
877.91
787.13
654.75
Trade Payables
726.07
749.53
782.13
638.61
541.05
356.88
323.48
274.35
215.98
181.10
Other Current Liabilities
304.61
261.08
193.19
200.85
194.25
153.16
113.60
69.84
93.43
79.21
Short Term Borrowings
922.56
1,054.24
810.88
765.58
409.27
371.69
454.21
525.10
473.83
392.85
Short Term Provisions
49.92
17.45
27.31
36.56
28.53
11.66
5.20
8.62
3.90
1.58
Total Liabilities
6,184.73
5,483.87
4,903.14
4,511.53
3,712.67
3,223.10
2,978.58
2,670.28
1,878.72
1,562.97
Net Block
2,426.47
2,095.62
1,910.92
1,541.17
1,332.00
1,203.97
944.25
776.73
644.34
559.94
Gross Block
3,882.08
3,351.81
2,981.22
2,461.77
2,145.15
1,875.23
1,472.94
1,199.63
983.66
822.98
Accumulated Depreciation
1,455.61
1,256.19
1,070.30
920.59
813.15
671.26
528.69
422.90
339.32
263.05
Non Current Assets
3,069.25
2,578.83
2,328.99
2,006.54
1,715.68
1,594.41
1,696.34
1,483.71
1,050.55
744.97
Capital Work in Progress
440.19
271.70
239.39
356.23
239.08
294.20
495.95
514.52
267.43
76.56
Non Current Investment
22.04
21.52
21.21
19.67
18.99
19.34
210.42
156.56
108.23
70.11
Long Term Loans & Adv.
179.51
190.00
157.47
89.47
125.61
76.89
45.72
35.91
30.56
38.37
Other Non Current Assets
1.04
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
3,115.48
2,905.05
2,574.15
2,504.99
1,997.00
1,518.85
1,282.24
1,186.57
828.16
818.00
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
1,342.82
1,300.55
1,149.41
978.55
782.18
438.43
384.21
279.95
269.18
253.72
Sundry Debtors
942.22
985.83
948.54
924.95
765.42
662.04
673.54
628.25
417.70
375.35
Cash & Bank
596.38
386.38
312.79
409.46
271.04
283.94
89.04
115.64
49.80
130.29
Other Current Assets
234.06
46.28
49.22
61.67
178.35
134.43
135.45
162.73
91.49
58.65
Short Term Loans & Adv.
180.15
186.00
114.19
130.35
127.61
91.83
98.46
114.09
51.66
48.68
Net Current Assets
1,112.32
822.75
760.65
863.38
823.90
625.45
385.76
308.65
41.03
163.25
Total Assets
6,184.73
5,483.88
4,903.14
4,511.53
3,712.68
3,113.26
2,978.58
2,670.28
1,878.71
1,562.97

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
866.57
439.41
738.75
332.06
432.48
476.19
262.24
-0.65
188.24
151.43
PBT
660.17
547.23
687.17
558.00
704.36
425.64
276.78
180.00
204.99
186.03
Adjustment
344.13
328.80
237.69
176.29
194.43
156.88
149.85
107.45
95.14
92.63
Changes in Working Capital
6.02
-246.32
-10.31
-257.19
-274.95
12.75
-75.94
-230.03
-52.37
-79.70
Cash after chg. in Working capital
1,010.32
629.71
914.55
477.11
623.84
595.27
350.69
57.42
247.77
198.97
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-143.75
-190.30
-175.80
-145.05
-191.37
-119.08
-88.45
-58.07
-59.53
-47.54
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-691.29
-360.16
-191.36
-380.12
-277.13
-160.63
-269.82
-462.31
-326.09
-161.65
Net Fixed Assets
-254.98
-101.04
-104.53
-302.61
-204.42
-124.57
-176.36
-282.01
-249.86
-75.62
Net Investments
-340.13
-264.87
-80.00
-5.00
-146.14
61.07
-431.34
-0.01
13.84
-16.48
Others
-96.18
5.75
-6.83
-72.51
73.43
-97.13
337.88
-180.29
-90.07
-69.55
Cash from Financing Activity
-92.51
7.66
-440.29
190.00
-299.31
-212.85
-17.43
528.62
55.87
85.67
Net Cash Inflow / Outflow
82.77
86.92
107.10
141.94
-143.97
102.70
-25.01
65.66
-81.98
75.44
Opening Cash & Equivalents
381.10
291.56
184.71
41.84
185.93
83.02
108.03
42.37
124.35
54.85
Closing Cash & Equivalent
466.11
381.10
291.56
184.71
41.84
185.93
83.02
108.03
42.37
130.29

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
152.63
132.33
116.38
103.62
86.85
71.80
59.73
51.17
39.40
29.20
ROA
8.60%
7.80%
10.97%
10.04%
15.84%
9.99%
6.64%
5.13%
8.12%
9.03%
ROE
14.52%
13.46%
19.18%
17.49%
27.64%
18.54%
13.32%
10.60%
18.23%
23.53%
ROCE
16.16%
15.66%
19.63%
17.37%
25.42%
17.22%
12.71%
11.09%
16.57%
20.16%
Fixed Asset Turnover
2.06
2.07
1.66
1.63
1.97
1.75
1.78
1.55
1.59
1.66
Receivable days
47.23
53.89
75.78
81.94
65.94
83.34
100.03
112.83
100.84
67.60
Inventory Days
64.75
68.26
86.07
85.35
56.39
51.34
51.03
59.23
66.49
63.11
Payable days
156.05
138.29
112.38
114.29
117.79
58.20
54.96
62.37
64.87
59.99
Cash Conversion Cycle
-44.08
-16.14
49.48
52.99
4.54
76.48
96.10
109.70
102.46
70.72
Total Debt/Equity
0.35
0.38
0.38
0.43
0.39
0.49
0.65
0.75
0.73
1.01
Interest Cover
7.39
6.17
13.29
25.04
27.80
16.75
10.72
6.44
7.36
6.02

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Granules India’s arm receives four observations from USFDA
    6th Apr 2026, 10:57 AM

    The observations are related to procedural matters and no data integrity - related observations

    Read More
  • Granules India’s arm receives VAI classification for Telangana facility
    1st Apr 2026, 09:59 AM

    The inspection is now closed, and no regulatory action has been recommended

    Read More
  • Granules India’s arm gets EIR with NAI status for packaging facility in US
    5th Mar 2026, 14:12 PM

    The FDA inspection was conducted at the company’s packaging facility in Manassas, Virginia, from December 1 to 3, 2025

    Read More
  • Granules India - Quarterly Results
    24th Jan 2026, 00:00 AM

    Read More
  • Granules India’s arm gets tentative approval for generic Amphetamine Extended-Release Tablets
    8th Jan 2026, 10:52 AM

    The product is indicated for the treatment of Attention Deficit Hyperactivity Disorder and has an estimated market size of around $41 million

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.